Be sure to read this story!
"The Cancer That Shouldn't Be"
Watch the fireworks Monday!
eventful week or so <gg>
be nice to regain 14/20.50 or so
bounced on the 200d and the longer term uptrend remains intact
predictive power of technicals stinks in a market like this however
hope everyone is hanging in there!
The action of the stock has no relation to expectations 0r reality. This just in from London.
FRANKFURT - Die Commerzbank hat die Aktien von QIAGEN mit "Buy" und einem Kursziel von 17 Euro bzw. 25 Dollar best�tigt. Eine Entscheidung zu Gunsten von QIAGEN in einem Kartellstreit mit Konkurrent Third Wave habe keine Ver�nderungen im Bewertungsmodell gebracht, schrieb Analyst Daniel Wendorff in einer Studie vom Montag. Die wichtigere Entscheidung im Patentstreit mit Third Wave in Bezug auf den HPV-Test stehe noch aus. Aufgrund der zu erwartenden Beschleunigung des Gewinnwachstums nach dem Digene (NASDAQ: DIGE - Nachrichten) -Kauf und der geringen Abh�ngigkeit vom Wirtschaftszyklus sei QIAGEN aber eine Kerninvestition.
This was also posted via the googlefinance page.
NEW YORK, January 14 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on Qiagen NV (QIA.ETR). The target price is set to $27.
In a research note published this morning, the analysts mention that the company has been granted summary judgment against Third Wave Technologies� antitrust counterclaims. Given Qiagen�s continued double-digit organic growth and 20%-30% operating margins, the company�s stock deserves to trade at a premium to that of its life science peers, the analysts believe.
reiterated guidance of 614-635 in this story:
and said merger on plan in this story:
so i think this is just market angst
can translate above here if you like:
dax down over 2%
not sure what the venue was but per german press sacker was meeting with insts in ny yesterday i believe...
i think consensus is 892 not 829...over 600 and over 800 isn't good enough given guidance/consensus so perhaps this is playing a role...
<<15-Jan-08 10:53 ET In Play Qiagen sees 2008 revenue significantly' exceeding $800 mln (consensus is $$829.79 mln) - Bloomberg (22.02 -1.37) : Qiagen says 2007 sales were more than $600 mln (consensus is $640.03 mln), says won't pay dividend for 2007>>
she coulda been a little nicer!
<<In her ruling, Judge Crabb noted that Third Wave provided no evidence that its failure to win more contracts is attributable to any illegal acts by QIAGEN, but rather to the customer's choice to purchase QIAGEN's FDA-approved test. According to Judge Crabb's ruling, QIAGEN ``is selling a product that many customers prefer over the product defendant is selling, with the not surprising result that defendant has not captured as many customers as it wishes it had.'' Judge Crabb's ruling went on to say that ``the law does not regulate customer choice or require businesses to improve the lot of their competitors.''
Mr. Schatz added that the Company will continue to aggressively pursue its pending patent litigation, in which QIAGEN alleges that Third Wave is infringing on QIAGEN intellectual property.>>
Focus please! This story came out before today's trading and accounts for Friday's positive price action in an otherwise ugly tape. I doubt there will be any fireworks Monday unless the overall market is unusually strong.